ERYPEG 50MCG INJECTION

Erypeg 50 mcg injection contains active components, such as Recombinant human EPOETIN ALFA/EPOETIN ALFA. It is a medication that belongs to a class of drugs called erythropoiesis-stimulating agents (ESAs). The medication is used to treat anaemia that is due to chronic kidney diseases (CKD), as well as chemotherapy for cancer or HIV treatment using zidovudine. It also reduces the requirement for transfusions of red blood cells for patients at risk of losing blood due to surgery planned and other therapies.
Erypeg 50 mcg injection shouldn’t be administered to patients suffering from uncontrolled hypertension or hypersensitivity active thrombotic microangiopathy (TMA) and Pure red cell cancer (PRCA) seizures that are uncontrolled and pregnancy or lactation. It is also recommended to use it carefully in patients who have a background of bleeding clots, heart disease, kidney disease, stroke, thalassemia, liver disease, sickle-cell anaemia, myelodysplastic syndrome, leukaemia or cancer. It is not recommended to use for children younger than 18 years old in cases where the benefits are more significant than the risks. Older adults taking this medication must be monitored closely for any adverse effects. Before you begin this medication, you must speak with your physician about the potential risks and advantages of the Erypeg 50mcg injection.